Exagen (NASDAQ:XGN) reported quarterly losses of $(0.20) per share which met the analyst consensus estimate. This is a 5.26 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $15.50 million which beat the analyst consensus estimate of $14.54 million by 6.56 percent. This is a 7.51 percent increase over sales of $14.41 million the same period last year.